Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03668847Phase 2Completed

DM-CHOC-PEN for Brain Tumors in AYA Subjects

Role: lead

NCT03371004Phase 1Completed

DM-CHOC-PEN Plus Radiation for Brain Tumors

Role: lead

NCT02038218Phase 2Completed

Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors

Role: lead

NCT02889445Unknown

A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers

Role: lead

NCT01976910Phase 1Completed

Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"

Role: lead

NCT01048008Phase 1Completed

Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer

Role: lead

NCT00002153Phase 1Completed

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

Role: lead

All 7 trials loaded